MXPA02002681A - Uso de metabolitos de acido alfa-linolenico para el tratamiento o prevencion del cancer. - Google Patents

Uso de metabolitos de acido alfa-linolenico para el tratamiento o prevencion del cancer.

Info

Publication number
MXPA02002681A
MXPA02002681A MXPA02002681A MXPA02002681A MXPA02002681A MX PA02002681 A MXPA02002681 A MX PA02002681A MX PA02002681 A MXPA02002681 A MX PA02002681A MX PA02002681 A MXPA02002681 A MX PA02002681A MX PA02002681 A MXPA02002681 A MX PA02002681A
Authority
MX
Mexico
Prior art keywords
cancer
medicament
prevention
manufacture
treatment
Prior art date
Application number
MXPA02002681A
Other languages
English (en)
Spanish (es)
Inventor
Mark Obukowicz
Original Assignee
Monsanto Technology Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Monsanto Technology Llc filed Critical Monsanto Technology Llc
Publication of MXPA02002681A publication Critical patent/MXPA02002681A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A23L33/12—Fatty acids or derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Polymers & Plastics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Food Science & Technology (AREA)
  • Oncology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
MXPA02002681A 1999-09-10 2000-09-11 Uso de metabolitos de acido alfa-linolenico para el tratamiento o prevencion del cancer. MXPA02002681A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/393,790 US6340705B1 (en) 1999-09-10 1999-09-10 Use of α-linolenic acid metabolites for treatment or prevention of cancer
PCT/US2000/024931 WO2001017517A2 (en) 1999-09-10 2000-09-11 Use of g(a)-linolenic acid metabolites in the manufacture of a medicament for the treatment or prevention of cancer

Publications (1)

Publication Number Publication Date
MXPA02002681A true MXPA02002681A (es) 2003-10-14

Family

ID=23556262

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA02002681A MXPA02002681A (es) 1999-09-10 2000-09-11 Uso de metabolitos de acido alfa-linolenico para el tratamiento o prevencion del cancer.

Country Status (9)

Country Link
US (2) US6340705B1 (https=)
EP (1) EP1237545B1 (https=)
JP (1) JP2003508484A (https=)
AT (1) ATE318133T1 (https=)
AU (1) AU7371600A (https=)
CA (1) CA2384502C (https=)
DE (1) DE60026152T2 (https=)
MX (1) MXPA02002681A (https=)
WO (1) WO2001017517A2 (https=)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040037892A1 (en) * 2001-11-19 2004-02-26 Adrianne Bendich Dietary composition containing conjugated linoleic acid and calcium for improved health
WO2002092779A2 (en) * 2001-05-17 2002-11-21 Pilot Therapeutics, Inc. Method for enriching tissues in long chain polyunsaturated fatty acids
US6977271B1 (en) * 2001-08-30 2005-12-20 Health Research, Inc. Method for inhibition of angiogenesis and vasculogenesis
GB0311081D0 (en) * 2003-05-14 2003-06-18 Btg Internat Limted Treatment of neurodegenerative conditions
CA2436650A1 (en) * 2003-08-06 2005-02-06 Naturia Inc. Conjugated linolenic acid (clnatm) compositions: synthesis, purification and uses
WO2005018632A1 (en) * 2003-08-18 2005-03-03 Btg International Limited Treatment of neurodegenerative conditions
CN102127057A (zh) * 2004-03-15 2011-07-20 武田药品工业株式会社 二肽基肽酶抑制剂
US20050266051A1 (en) * 2004-05-27 2005-12-01 The Procter & Gamble Company Pet food compositions and methods
US7456270B2 (en) * 2004-09-01 2008-11-25 Abbott Laboratories Δ6-desaturase genes and uses thereof
DE202004015931U1 (de) * 2004-10-13 2005-01-05 Dr. Gerhard Mann Chem.-Pharm. Fabrik Gmbh Omega-3-Fettsäuren und Omega-6-Fettsäuren enthaltende Zusammensetzung
GB0425932D0 (en) * 2004-11-25 2004-12-29 Btg Int Ltd Structured phospholipids
US8092839B2 (en) * 2004-12-13 2012-01-10 Swing Aerobics Licensing, Inc. Medicament for treatment of cancer and other diseases
US8431165B2 (en) * 2004-12-13 2013-04-30 Swing Aerobics Licensing, Inc. Medicament for treatment of cancer and other diseases
GB0504362D0 (en) * 2005-03-02 2005-04-06 Btg Int Ltd Cytokine modulators
GB0504333D0 (en) * 2005-03-02 2005-04-06 Btg Int Ltd Treatment of cytokine dysregulation
US7481870B2 (en) * 2006-04-18 2009-01-27 Oreck Holdings, Llc Electrode wire for an electrostatic precipitator
EP2026828B1 (en) 2006-06-08 2015-04-15 The Procter and Gamble Company Use of at least one polyphenol for promoting eye health
FR2904554B1 (fr) * 2006-08-04 2010-11-05 Zheng Xu Lipides moleculaires heterogenes cytotropes (lmhc), procede de preparation, et methodes de traitement de patients porteurs de cancers multiples
US20100010088A1 (en) * 2007-11-01 2010-01-14 Wake Forest University School Of Medicine Compositions and Methods for Prevention and Treatment of Mammalian Diseases
US8343753B2 (en) * 2007-11-01 2013-01-01 Wake Forest University School Of Medicine Compositions, methods, and kits for polyunsaturated fatty acids from microalgae
NZ586249A (en) * 2007-12-19 2012-05-25 Prometic Biosciences Inc A combination of medium-chain length fatty acids, salts or triglycerides, gemcitabine, and optionally erlotinib, for the treatment of pancreatic cancer
US20090197955A1 (en) * 2008-01-31 2009-08-06 Monsanto Company Methods of improving dha deposition and related function and/or development
US8060617B2 (en) * 2008-12-19 2011-11-15 Cisco Technology, Inc. Reserving network resources during scheduling of meeting event
US8372465B2 (en) 2010-02-17 2013-02-12 Bunge Oils, Inc. Oil compositions of stearidonic acid
EP2425833A1 (de) * 2010-09-03 2012-03-07 Fresenius Kabi Deutschland GmbH Die intravenöse Applikation von Fischöl/DHA +EPA vor bzw. mit Beginn der Chemotherapie
WO2012141575A1 (en) * 2011-04-14 2012-10-18 N.V.Nutricia Combination of epa, dpa and/or dha with a chemotherapeutic agent
US10076550B2 (en) * 2014-06-25 2018-09-18 Council Of Scientific & Industrial Research Synergistic pharmaceutical composition for gastroinestinal disorders

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8302708D0 (en) * 1983-02-01 1983-03-02 Efamol Ltd Pharmaceutical and dietary composition
HU203660B (en) * 1987-04-23 1991-09-30 Biogal Gyogyszergyar Improved process for producing food-additive composition rich in omega-3-unsaturated fatty acids
CN1035925C (zh) * 1988-11-16 1997-09-24 许正 亲细胞非均质分子脂质的制备方法
ES2059880T3 (es) * 1990-05-23 1994-11-16 Nestle Sa Utilizacion del acido estearidonico para el tratamiento de las enfermedades inflamatorias.
GB9012651D0 (en) * 1990-06-06 1990-07-25 Efamol Holdings Essential fatty acid treatment
EP0585058A1 (en) * 1992-08-25 1994-03-02 Scotia Holdings Plc Pharmaceutical compositions containing fatty acids and heparin
EP0585057A1 (en) * 1992-08-25 1994-03-02 Scotia Holdings Plc Lithium salts of fatty acids for the treatment of viral infections and cancer
CA2119000A1 (en) 1993-03-19 1994-09-20 David Frederick Horrobin Formulation for use in smokers
US5925669A (en) * 1994-03-22 1999-07-20 Molecular/Structural Bio Technologies, Inc. Carrier compositions for anti-neoplastic drugs
JPH0853351A (ja) * 1994-08-11 1996-02-27 Sagami Chem Res Center 酵素阻害剤、血管新生抑制剤、および癌転移抑制剤
KR970002037B1 (ko) * 1994-12-09 1997-02-21 농촌진흥청 들깨유로부터 α-리놀렌산(ALA)을 분리, 정제하는 방법
US5639787A (en) * 1995-02-28 1997-06-17 The Center For The Improvement Of Human Functioning Int'l, Inc. Therapeutic method for the treatment of cancer
US6077828A (en) 1996-04-25 2000-06-20 Abbott Laboratories Method for the prevention and treatment of cachexia and anorexia
DE69622722T2 (de) 1996-11-20 2003-02-27 N.V. Nutricia, Zoetermeer Fette enthaltende Ernährungszusammensetzung zur Behandlung des Stoffwechselsyndroms
DE19757414A1 (de) * 1997-12-23 1999-07-01 Nutricia Nv Fettmischung

Also Published As

Publication number Publication date
WO2001017517A2 (en) 2001-03-15
EP1237545B1 (en) 2006-02-22
US20020010211A1 (en) 2002-01-24
DE60026152T2 (de) 2006-11-16
AU7371600A (en) 2001-04-10
ATE318133T1 (de) 2006-03-15
WO2001017517A3 (en) 2002-07-11
EP1237545A2 (en) 2002-09-11
US6340705B1 (en) 2002-01-22
JP2003508484A (ja) 2003-03-04
CA2384502A1 (en) 2001-03-15
CA2384502C (en) 2011-01-18
DE60026152D1 (de) 2006-04-27

Similar Documents

Publication Publication Date Title
MXPA02002681A (es) Uso de metabolitos de acido alfa-linolenico para el tratamiento o prevencion del cancer.
AU2002225772A1 (en) Therapeutic agents and methods of use thereof for treating an amyloidogenic disease
IL256054A (en) A pharmaceutical preparation containing dextromethorphan and quinidine for the treatment of nervous disorders
SG54210A1 (en) Oral composition for the treatment of bowel inflammatory bowel diseases
TW371628B (en) Composition for treating condyloma acuminata
NZ516349A (en) Conjugates of phytosterol or phytostanol with ascorbic acid and use thereof in treating or preventing cardiovascular disease
NZ334124A (en) Use of the chelating agent clioquinol, with vitamin B12 for the manufacture of a pharmaceutical composition for the treatment of alzheimer's disease
EP1259240B8 (en) Agents, such as nicotinamide or cadpr for the treatment of skin disorders
DE60128912D1 (en) Pyridoxin- und pyridoxalanaloga als cardiovasculäre therapeutika
WO2001030802A3 (en) Therapeutic treatments comprising administration of certain steroids for blood cell deficiencies
MY111260A (en) Pharmaceutical composition for the treatment of nicotine dependence
BG106057A (en) Method of enhancing the efficacy of anti-tumour agents
AP2001002377A0 (en) Substituted phenoxyacetic acids.
HK1049105A1 (zh) 磷酸二酯酶4抑制剂的使用方法
UA72927C2 (uk) Композиція для лікування печінково-клітинного раку, що містить доцетаксель
IL126159A (en) Pharmaceutical composition containing duloxetine for treating or preventing interstitial cystitis
AU2001241315A1 (en) Use of a composition
NZ515173A (en) Treatment of hypersensitivity reaction disorders
TR200200987T2 (tr) Kanser tedavisine yönelik,ornatılmış pirroller
EP1374873B8 (en) The use of n-acetyl-d-glucosamine in the manufacture of pharmaceutical useful for supressing side-effect of radiotherapy and chemotherapy
EP0946174A4 (en) TREATMENT OF URINE INCONTINENCE AND COMPOSITIONS THEREFOR
JO2296B1 (en) Substituted pyrolates
GB0128071D0 (en) Medicament
WO2002076405A3 (en) Compositions and methods of treatment of ulcerating diseases, burns, and related conditions
UA34199A (uk) Спосіб лікування пародонтиту

Legal Events

Date Code Title Description
FG Grant or registration